cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kinnate Biopharma Inc
2 own
2 watching
Current Price
$0
$0.4
(5.48%)
logo-knte
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
322.4M
52-Week High
52-Week High
15.86
52-Week Low
52-Week Low
5.17
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization322.4M
icon52-Week High15.86
icon52-Week Low5.17
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Kinnate Biopharma Inc do?
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Read More
How much money does Kinnate Biopharma Inc make?
News & Events about Kinnate Biopharma Inc.
Globe Newswire
9 months ago
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the ...
Zolmax
1 year ago
JPMorgan Chase & Co. increased its stake in Kinnate Biopharma Inc. (NASDAQ:KNTE) by 60.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,147 shares of the companys stock after acquiring an additional 3,079 shares during the period. JPMorgan Chase...
Zolmax
1 year ago
JPMorgan Chase & Co. grew its position in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) by 60.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,147 shares of the companys stock after acquiring an additional 3,079 shares during the ...
Frequently Asked Questions
Frequently Asked Questions
What is Kinnate Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Kinnate Biopharma Inc shares?
plus_minus_icon
How can I buy Kinnate Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Kinnate Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Kinnate Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Kinnate Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Kinnate Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Kinnate Biopharma Inc?
plus_minus_icon
What percentage is Kinnate Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Kinnate Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.4
(5.48%)
logo-knte
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00